EA029757B1 - ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ Download PDF

Info

Publication number
EA029757B1
EA029757B1 EA201691164A EA201691164A EA029757B1 EA 029757 B1 EA029757 B1 EA 029757B1 EA 201691164 A EA201691164 A EA 201691164A EA 201691164 A EA201691164 A EA 201691164A EA 029757 B1 EA029757 B1 EA 029757B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazolo
pyridin
carboxylic acid
yloxy
dioxo
Prior art date
Application number
EA201691164A
Other languages
English (en)
Russian (ru)
Other versions
EA201691164A1 (ru
Inventor
Роберт Л. Хадкинс
Эллисон Л. Зулли
Original Assignee
Игнита, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Игнита, Инк. filed Critical Игнита, Инк.
Publication of EA201691164A1 publication Critical patent/EA201691164A1/ru
Publication of EA029757B1 publication Critical patent/EA029757B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201691164A 2013-12-26 2014-12-18 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA029757B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (2)

Publication Number Publication Date
EA201691164A1 EA201691164A1 (ru) 2016-12-30
EA029757B1 true EA029757B1 (ru) 2018-05-31

Family

ID=52293273

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691164A EA029757B1 (ru) 2013-12-26 2014-12-18 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201890061A EA201890061A3 (ru) 2013-12-26 2014-12-18 Производные пиразоло[1,5-a]пиридина и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890061A EA201890061A3 (ru) 2013-12-26 2014-12-18 Производные пиразоло[1,5-a]пиридина и способы их применения

Country Status (22)

Country Link
US (2) US9914731B2 (enExample)
EP (2) EP3087070B1 (enExample)
JP (1) JP2017500362A (enExample)
KR (1) KR20160110390A (enExample)
CN (1) CN106029661B (enExample)
AU (1) AU2014370186A1 (enExample)
BR (1) BR112016015057A2 (enExample)
CA (1) CA2934667A1 (enExample)
CL (1) CL2016001604A1 (enExample)
DK (1) DK3087070T3 (enExample)
EA (2) EA029757B1 (enExample)
ES (1) ES2654931T3 (enExample)
HU (1) HUE037579T2 (enExample)
IL (1) IL246311A0 (enExample)
MX (1) MX2016008445A (enExample)
NO (1) NO3014707T3 (enExample)
PH (1) PH12016501232A1 (enExample)
PL (1) PL3087070T3 (enExample)
PT (1) PT3087070T (enExample)
SG (1) SG11201605207PA (enExample)
SI (1) SI3087070T1 (enExample)
WO (1) WO2015100117A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000808A2 (pt) * 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CN106467541B (zh) 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
EP3558991A2 (en) * 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11623923B2 (en) * 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
JP7542613B2 (ja) * 2019-09-06 2024-08-30 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ Axlとc-Metキナーゼ阻害活性を有する化合物およびその製造と使用
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022019517A2 (pt) 2020-03-30 2022-12-06 Hutchison Medipharma Ltd Compostos de amida e usos dos mesmos
JP7802077B2 (ja) * 2021-07-13 2026-01-19 日本曹達株式会社 ウラシル化合物の製造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l,2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
AU2024319770A1 (en) 2023-08-07 2026-02-19 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
EA030141B1 (ru) * 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
MA34969B1 (fr) * 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
WO2013022519A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
US9914731B2 (en) 2018-03-13
AU2014370186A1 (en) 2016-07-14
US20160318929A1 (en) 2016-11-03
PL3087070T3 (pl) 2018-03-30
SG11201605207PA (en) 2016-07-28
WO2015100117A1 (en) 2015-07-02
CN106029661B (zh) 2017-11-03
ES2654931T3 (es) 2018-02-15
EP3087070B1 (en) 2017-11-08
CA2934667A1 (en) 2015-07-02
CL2016001604A1 (es) 2017-05-26
IL246311A0 (en) 2016-08-02
SI3087070T1 (en) 2018-01-31
KR20160110390A (ko) 2016-09-21
PH12016501232A1 (en) 2016-08-15
BR112016015057A2 (pt) 2017-08-08
EP3309160A1 (en) 2018-04-18
DK3087070T3 (en) 2017-12-04
MX2016008445A (es) 2016-10-28
HUE037579T2 (hu) 2018-09-28
EA201890061A2 (ru) 2018-05-31
EP3087070A1 (en) 2016-11-02
JP2017500362A (ja) 2017-01-05
EA201691164A1 (ru) 2016-12-30
NO3014707T3 (enExample) 2018-01-06
AU2014370186A2 (en) 2016-07-21
EA201890061A3 (ru) 2018-09-28
CN106029661A (zh) 2016-10-12
PT3087070T (pt) 2018-01-30
US20180148447A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EA029757B1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP6903790B2 (ja) Fgfr抑制剤としての二環式複素環
AU2016219822B2 (en) Bicyclic heterocycles as FGFR inhibitors
DK2805940T3 (en) PYRAZINE CARBOXAMIDE COMPOUND
US8933103B2 (en) Pyridone derivatives
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
JP2023510929A (ja) ヘテロアリール誘導体、その製造方法およびその使用
KR20190014505A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
JP2018528195A (ja) 置換キノロン誘導体またはその薬学的に許容される塩もしくはその立体異性体、並びにその医薬組成物及び応用
CN107922431A (zh) Hpk1抑制剂及其使用方法
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
CN113773308A (zh) Rho激酶抑制剂
AU2012288969A1 (en) Substituted quinolines and their use as medicaments
JP2019507766A (ja) 線維症の治療のための新規化合物及びその医薬組成物
CN103012399A (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
TWI869674B (zh) 雜芳基衍生化合物及其用途
KR102731945B1 (ko) 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물
HK40064586A (en) Rho kinase inhibitors
HK40062732A (en) Rho kinase inhibitors
HK40062730A (en) Rho kinase inhibitors
HK40040495A (en) Pyrazole derivatives as malt1 inhibitors
EA050669B1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU